Boryung Signs A CDMO Agreement With Lotus Pharmaceutical To Leverage Anti-Cancer Drug Manufacturing Capabilities For Global Market Reach

• Boryung, a leader in localizing anti-cancer drugs, demonstrates manufacturing competitiveness by entering the CDMO business
• EU-GMP Certified Yesan Plant to supply anti-cancer drug in 2026

Boryung announced the signing of a contract manufacturing agreement with Lotus Pharmaceutical Co. (Lotus) in Taiwan. Lotus is one of the leading pharmaceutical company in Taiwan, specializing in oncology treatment.

Under this agreement, Boryung is responsible for manufacturing injectable anti-cancer drugs for Lotus. Boryung plans to supply the product starting in 2026, following the completion of the approval process. This achievement underscores the global recognition of Boryung's manufacturing capabilities for strategic essential drugs, building on its existing manufacturing and distribution capacity in South Korea.

This CDMO agreement marks Boryung's initial step into the global CDMO business of acquiring strategic original essential drugs, internalizing production and supplying them globally. It is expected to be a pivotal milestone in accelerating the company's strategic growth plan.

Production will be conducted at Boryung's EU-GMP-certified Yesan Plant in South Korea, a cutting-edge manufacturing facility with an annual capacity of 6 million vials. The facility features a SPINE structure designed by Novo Nordisk Engineering (NNE), a global pharmaceutical facility design and engineering company, to maximize the efficiency and connectivity of the production process. Also, the automatic IBC (Intermediate Bulk Container) BIN system automates the entire process from raw material weighing to packaging, eliminating the risk of contamination and cross-contamination.

Based on the Yesan Plan, Boryung aims to obtain EU-GMP certification for oral drugs in 2025 and its existing EU-GMP certification for cytotoxic anti-cancer injectables to stably supply the major anti-cancer drugs and to target the global market.

Sungjin Kim, Chief Strategy Officer of Boryung, stated, "This CDMO contract confirms Boryung's globally recognized manufacturing capabilities and reliability," adding, “We will further reinforce our differentiated CDMO business by manufacturing and globally supplying original essential drugs."

Meanwhile, Boryung has acquired key original essential drugs based on the Legacy Brands Acquisition (LBA) strategy since 2020. Along with this agreement, Boryung is proactively advancing its expanded LBA strategy by internalizing the production of acquired original drugs and establishing a model to supply them to international markets.